Eisai To Shut Down H3 In Global R&D Restructuring
New Structure From October; New Astellas W Coast Campus
Executive Summary
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.